Molnupiravir Plus Usual Care vs Usual Care Alone as Early Treatment for Adults With COVID-19 at Increased Risk of Adverse Outcomes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Lancet 2022 Dec 22;[EPub Ahead of Print], CC Butler, FDR Hobbs, OA Gbinigie, NM Rahman, G Hayward, DB Richards, J Dorward, DM Lowe, JF Standing, J Breuer, S Khoo, S Petrou, K Hood, JS Nguyen-Van-Tam, MG Patel, BR Saville, J Marion, E Ogburn, J Allen, H Rutter, N Francis, NPB Thomas, P Evans, M Dobson, TA Madden, J Holmes, V Harris, ME Png, M Lown, O van Hecke, MA Detry, CT Saunders, M Fitzgerald, NS Berry, L Mwandigha, U Galal, S Mort, BD Jani, ND Hart, H Ahmed, D Butler, M McKenna, J Chalk, L Lavallee, E Hadley, L Cureton, M Benysek, M Andersson, M Coates, S Barrett, C Bateman, JC Davies, I Raymundo-Wood, A Ustianowski, A Carson-Stevens, LM Yu, P LittleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.